Navigation Links
Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
Date:11/10/2011

SAN FRANCISCO, CA NOVEMBER 10, 2011 The cost effectiveness of transcatheter aortic valve implantation (TAVR) compared to surgical aortic valve replacement (SAVR) depends on whether TAVR is performed via the femoral artery or transapically, through a small incision in the chest, according to a new study.

Recently, transcatheter aortic valve implantation (TAVR) has been shown to result in similar 12-month survival as surgical aortic valve replacement (SAVR) for high-risk patients with severe aortic stenosis. The potential cost-effectiveness of TAVR versus SAVR in the PARTNER trial was examined and the results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

The PARTNER trial randomized patients with severe, symptomatic aortic stenosis and high surgical risk to either TAVR (N=348) or SAVR (N=351) and followed them for a minimum of 12 months. Health state utilities were estimated using the EuroQOL (EQ-5D) at baseline, one, six, and 12 months. Detailed medical resource utilization data were collected on all study patients, and hospital billing data were collected for both index and follow-up hospitalizations for any cause from consenting U.S. patients.

The objectives of the study were to combine cost data with survival and Quality of Life (QoL) data to estimate the12-month cost-effectiveness of TAVR compared with AVR and to explore potential differences in costs and cost-effectiveness of TAVR vs. AVR for the transfemoral vs. transapical populations.

Among high risk aortic stenosis patients eligible for the transfemoral approach, TAVR, compared with surgical AVR:

  • Provided small but significant gains in 12 month quality-adjusted life expectancy (0.06 0.07 Quality Adjusted Life Years, QALYs)
  • Was associated with higher procedural costs but slightly lower index hospitalization and total 12 month costs

However, not all patients qualify medically for the transfemoral approach. Among patients only eligible for the transapical approach:

  • TAVR provided no increase (and possible decrease) in QALYs
  • TAVR increased procedural, index admission, and 12 month costs (by ~$10,000/patient)

"Results of this trial indicate that for patients with severe aortic stenosis and high surgical risk, transcatheter aortic valve replacement is an economically attractive and possibly dominant strategy compared with surgical aortic valve replacement, provided that patients are suitable for the transfemoral approach," said Matthew R. Reynolds, MD. Dr. Reynolds is Director of the Economics and Quality of Life Research Center at Harvard Clinical Research Institute (HCRI), an Assistant Professor of Medicine at Harvard Medical School and Associate Director of Electrophysiology at the Boston VA Health Care System.

"Current results for transcatheter aortic valve replacement via the transapical approach, compared with surgical aortic valve replacement, are unattractive from a health economic perspective," said Dr. Reynolds.

"Whether the transapical approach can be refined to provide faster recovery and better results from a cost perspective should be the subject of further study."


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Combination epigenetic therapy clinical trial results
2. Results of the PARIS registry Reported at TCT 2011
3. Results of the TRIGGER-PCI trial reported at TCT 2011
4. Results of rapid gene trial reported at TCT 2011
5. Results of the BRIDGE trial reported at TCT 2011
6. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
7. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
8. E-counselling shows dramatic results in lowering blood pressure
9. Less Frequent Mammograms May Lower False-Positive Results
10. Mayo Clinic wins grant to study ethics of sharing genetic test results with relatives
11. TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement is a necessary ... is paramount to success. Selecting an inappropriate measurement method can cause costly errors, ... the same equipment. Rare or expensive substances are wasted and production may even ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers ... Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. ... bodybuilder in 2012 and in less than a year was able to turn professional, ...
(Date:1/23/2017)... ... 23, 2017 , ... “The Inn at the Mill”: a story of love and redemption, ... to become happy and content. , “The Inn at the Mill” is the creation ... Germany and Vermont and is now living in Berks County on Crow Hill. ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: ... from an early age. “Life Under Blankets” is the creation of published author, Kimberly ... Circle Campus in Chicago. She went on to pursue a master’s degree in education ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to take an exotic journey ... world with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago ... and moisturizing vegetal coral to create this gentle, velvety body cream to envelop the ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Massachusetts , January 23, 2017 Longer life ... growth in the global market for medical device technologies. BCC Research ... in the Asia-Pacific region, should see strong growth ... and rising disposable incomes. Continue Reading ... ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... and PALMA, Spain , January ... S.L., a clinical-stage biopharmaceutical company focused on treatments ... patient has been enrolled in the Phase IIb ... for the treatment of cardiovascular calcification (CVC) in ... Most ESRD patients, in the last stage of ...
Breaking Medicine Technology: